Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication

Journal of Virology

Volumn 86, Issue 12, 2012, Pages 6835-6846

  Freel, Stephanie A ^a,b   Picking, Ralph A ^b   Ferrari, Guido ^b   Ding, Haitao ^d   Ochsenbauer, Christina ^d   Kappes, John C ^d   Kirchherr, Jennifer L ^a,b   Soderberg, Kelly A ^a,b   Weinhold, Kent J ^a,b   Cunningham, Coleen K ^b   Denny, Thomas N ^a,b   Crump, John A ^b,c   Cohen, Myron S ^e   McMichael, Andrew J ^f   Haynes, Barton F ^a,b   Tomaras, Georgia D ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Surgery ^*  (United States)

^c KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL CONTACT; CLADISTICS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SUPERNATANT; UPREGULATION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COHORT STUDIES; DOWN-REGULATION; FEMALE; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; VIRUS REPLICATION; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864012556     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00437-12     Document Type: Article

References (59)

1. + T-cell polyfunctionality and HIV-suppressive activity. Blood 113: 6351-6360.
2. + T cells. Blood 107:4781- 4789.
3. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103- 6110.
4. + T cell immunity and viral escape following acute HIV-1 infection. J. Immunol. 171:3837-3846.
5. Chakraborty H, et al. 2001. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 15:621- 627.
6. Chen H, et al. 2009. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J. Virol. 83:3138 -3149.
7. + T cells: implications for the development of therapeutic strategies. Proc. Natl. Acad. Sci. U. S. A. 98: 253-258.
8. + T cells. Science 270:1811-1815.
9. + T cells are associated with asymptomatic HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 97:13812- 13817.
10. Cohen MS, et al. 2011. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365:493-505.
11. Deeks SG, Walker BD. 2007. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27:406-416.
12. Derdeyn CA, et al. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
13. DeVico AL, Gallo RC. 2004. Control of HIV-1 infection by soluble factors of the immune response. Nat. Rev. Microbiol. 2:401- 413.
14. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667- 673.
15. Edmonds TG, et al. 2010. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408:1-13.
16. Ferrari G, et al. 2011. Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog. 7:e1001273. doi:10.1371/ journal.ppat.1001273.
17. Fiebig EW, et al. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17:1871-1879.
18. Freel SA, et al. 2010. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J. Virol. 84:4998 -5006.
19. Ganesan A, et al. 2010. Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J. Infect. Dis. 201:272- 284.
20. Geiben-Lynn R, et al. 2003. HIV-1 antiviral activity of recombinant natural killer cell enhancing factors, NKEF-A and NKEF-B, members of the peroxiredoxin family. J. Biol. Chem. 278:1569 -1574.
21. +) cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by beta-chemokines. J. Virol. 75:8306-8316.
22. Goonetilleke N, et al. 2009. The first T cell response to transmitted/ founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206:1253-1272.
23. Gray RH, et al. 2001. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357:1149 -1153.
24. Hansen SG, et al. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-527.
25. + T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood 117:3799 -3808.
26. Horuk R, et al. 1998. The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J. Biol. Chem. 273:386 -391.
27. +) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991-998.
28. Julg B, et al. 2010. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J. Virol. 84:5540 -5549.
29. Keele BF, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
30. + T cells. J. Virol. 85:1696 -1705.
31. + lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog. 6:e1000747. doi:10.1371/ journal.ppat.1000747.
32. Koup RA, et al. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
33. Li F, et al. 2006. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 24:6893- 6904.
34. Li H, et al. 2010. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog. 6:e1000890. doi:10.1371/journal. ppat.1000890.
35. Li M, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccineelicited neutralizing antibodies. J. Virol. 79:10108-10125.
36. + cell antiviral factor. Cell Immunol. 153:329 -343.
37. Malhotra U, et al. 2007. Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. J. Virol. 81:5225-5237.
38. Martins MA, et al. 2010. T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J. Virol. 84:4352- 4365.
39. +T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29:1009 -1021.
40. Ochsenbauer C, et al. 2012. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T-lymphocytes and monocyte-derived macrophages. J. Virol. 86:2715-2728.
41. Overman RG, Llorens AL, Greenberg ML, Garcia-Blanco MA, Tomaras GD. 2007. Initiation of human immunodeficiency virus type 1 (HIV-1) transcription is inhibited by noncytolytic CD8 suppression. Open Virol. J. 1:1-7.
42. Pilcher CD, et al. 2004. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189:1785-1792.
43. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. 2009. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J. Virol. 83:8289-8292.
44. Quinn TC, et al. 2000. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 342:921-929.
45. + T-cell epitopes in acute clade C virus infection. J. Infect. Dis. 204:768 -776.
46. + T cells from HIV controllers. Blood 118:955-964.
47. Saez-Cirion A, et al. 2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. U. S. A. 104:6776- 6781.
48. Saez-Cirion A, et al. 2009. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J. Immunol. 182:7828 -7837.
49. Salazar-Gonzalez JF, et al. 2009. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206:1273-1289.
50. +) T-lymphocyte mediated suppression of HIV-1 replication. Virology 405:234 -242.
51. +) T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage. Cell. Immunol. 266:154 -164.
52. Seder RA, Darrah PA, Roederer M. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8:247- 258.
53. Spentzou A, et al. 2010. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J. Infect. Dis. 201:720 -729.
54. + T cell mediated noncytolytic inhibition of human immunodeficiency virus type I. Front. Biosci. 6:D575-D598.
55. + T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. Proc. Natl. Acad. Sci. U. S. A. 97:3503-3508.
56. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896 -1905.
57. + anti-HIV-1 suppressor activity (CASA). Clin. Exp. Immunol. 127:145-150.
58. + T-cell suppression of SIV viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog. 6:e1000748. doi:10.1371/journal.ppat.1000748.
59. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 71:3120 -3128.